Human Leukocyte Antigen Alloimmunization and Alloimmune Platelet Refractoriness

Area of Science:

• Immunology
• Hematology
• Transfusion Medicine

Background:

• Transfusion refractoriness impacts up to 14% of hematological patients undergoing platelet transfusions.
• Human Leukocyte Antigen (HLA) alloimmunization is a primary driver of immune platelet refractoriness.
• While leukoreduction reduces HLA alloimmunization rates, pathogen reduction has shown no such effect.

Purpose of the Study:

• To review the pathophysiology of HLA alloimmunization and alloimmune refractoriness.
• To explore current and future strategies for preventing and treating HLA alloimmune refractoriness.
• To identify gaps in the evidence supporting existing prevention and treatment options.

Main Methods:

• Literature review focusing on pathophysiology, prevention, and treatment of HLA alloimmunization.
• Discussion of preclinical and clinical evidence for various management strategies.
• Analysis of current clinical practices for managing HLA alloimmune refractoriness.

Main Results:

• HLA alloimmunization is a significant complication of platelet transfusions in hematological patients.
• HLA-selected platelet transfusions are the standard management for patients with HLA alloimmune refractoriness.
• Pathogen reduction technologies do not mitigate HLA alloimmunization despite preclinical promise.

Conclusions:

• Understanding HLA alloimmunization is crucial for managing transfusion refractoriness.
• Further research is needed to address existing gaps in prevention and treatment strategies.
• Future directions may involve novel approaches to prevent and treat alloimmune refractoriness.